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ABSTRACT
Objectives Patients with type 2 diabetes have a higher 
risk of colorectal cancer (CRC), but whether Chinese herbal 
medicines (CHMs) can reduce this risk is unknown. This 
study investigated the effect that CHMs have on CRC risk 
in patients with type 2 diabetes.
Research design and methods This cohort study 
used the Taiwanese National Health Insurance Research 
Database to identify 54 744 patients, newly diagnosed with 
type 2 diabetes, aged 20–70 years, who were receiving 
treatment between 1998 and 2007. From this sample, 
we randomly selected 14 940 CHMs users and 14 940 
non- CHMs users, using propensity scores matching. All 
were followed through 2012 to record CRC incidence. Cox 
proportional hazards regression was used to compute the 
hazard ratio (HR) of CRC by CHMs use.
Results During follow- up, 235 CHMs users and 375 non- 
CHMs users developed CRC, incidence rates of 1.73% 
and 2.47% per 1000 person- years, respectively. CHM 
users had a significantly reduced risk of CRC compared 
with non- CHM users (adjusted HR=0.71; 95% CI 0.60 to 
0.84). The greatest effect was in those receiving CHMs for 
more than 1 year. Huang- Qin, Xue- Fu- Zhu- Yu- Tang, Shu- 
Jing- Huo- Xue- Tang, Liu- Wei- Di- Huang- Wan, Ji- Sheng- 
Shen- Qi- Wan, Gan- Lu- Yin, Shao- Yao- Gan- Cao- Tang and 
Ban- Xia- Xie- Xin- Tang were significantly associated with 
lower risk of CRC.
Conclusion Integrating CHMs into the clinical 
management of patients with type 2 diabetes may be 
beneficial in reducing the risk of CRC.
InTROduCTIOn
Diabetes mellitus has become an increasingly 
prevalent chronic condition that affects more 
than 400 million people worldwide.1 Over the 
past 50 years, numerous studies have linked 
diabetes, in particular type 2 diabetes, to a 
higher risk of cancer. It is noteworthy that 
the risk of colorectal cancer (CRC), the third 
most common cancer around the world, 
is estimated to be 27% higher in patients 
with type 2 diabetes than in non- diabetic 
control patients.2 According to the WHO, 
approximately 1.8 million patients are newly 
diagnosed with CRC, and over 800 000 die 
annually from this cancer.3
In Taiwan, CRC is commonly diagnosed and 
is the third leading cause of cancer- related 
death. Massive developments in specialized 
diagnostic and therapeutic methods have 
improved the survival of patients with type 
2 diabetes. Some studies have indicated that 
the long- term use of insulin or sulfonylureas 
may predispose patients with type 2 diabetes 
to develop CRC.4 5 In view of this concern, it is 
Significance of this study
What is already known about this subject?
 ► Despite recent improvements in diabetes treatment, 
those with type 2 diabetes are still found to have 
higher risk of cancer, especially colorectal cancer 
(CRC).
 ► Recently, Chinese herbal medicines have become 
increasingly popular as an adjunctive treatment for 
patients with chronic diseases; nevertheless, as-
sociation of Chinese herbal medicines and the risk 
of CRC among patients with type 2 diabetes is still 
unknown.
What are the new findings?
 ► This retrospective 15- year cohort study clarified 
the therapeutic effect of Chinese herbal medicines 
on the subsequent risk of CRC among patients with 
type 2 diabetes.
 ► The most prominent effect was observed among 
those receiving Chinese herbal medicines for more 
than 1 year.
How might these results change the focus of 
research or clinical practice?
 ► The reported findings serve an important role for 
healthcare providers in helping to guide more ef-
fective treatment strategies to improve clinical out-
comes for patients with type 2 diabetes.
 ► The corresponding findings could serve as a refer-
ence for further pharmacological studies and clinical 
trials.
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Figure 1 Flowchart of study and follow- up of study 
participants. CHMs, Chinese herbal medicines; NHI, National 
Health Insurance.
of therapeutic interest to explore alternative treatments 
that may lessen this risk.
With few side effects, Chinese herbal medicines 
(CHMs) had been used for patients with chronic illnesses 
such as dementia,6 hepatocellular carcinoma7 and 
vertigo.8 Several randomized clinical trials have further 
suggested that CHMs could delay the progression of 
distal symmetric polyneuropathy9–11 and nephropathy.12 
More specifically, research findings have suggested that 
CHMs protect against CRC risk by improving the anti-
tumor activity of the chemotherapy drug 5- fluorouracil 
against the HT-29 colon cancer cell,13 implying that CHMs 
should not be neglected in the treatment of patients with 
type 2 diabetes.
Given the possible beneficial effect of CHMs on 
subsequent CRC risk, and the limited information on 
whether CHMs could modify the relationship between 
type 2 diabetes and CRC risk, findings from a long- term 
population- based cohort study might be useful in allo-
cating medical resources and in instituting fact- based 
policymaking for the treatment of CRC among patients 
with type 2 diabetes. Nevertheless, to date, no clinical 
observations or empirical data have documented this 
potential benefit for patients with type 2 diabetes. There-
fore, in this study, we analyzed a nationwide population- 
based database to compare the risk of CRC among 
patients with type 2 diabetes who either did or did not 
receive CHMs.
ReseaRCH desIgn and meTHOds
data source
For this study, we used a publicly released cohort dataset, 
the Longitudinal Health Insurance Database (LHID), 
comprised of approximately 1 000 000 randomly sampled 
people and obtained all records from 1996 to 2012. The 
database has been confirmed by the National Health 
Research Institute to be representative of the Taiwanese 
population and its data have been used in many previously 
published scientific papers.14 The encrypted information 
protects patient privacy and allows linkage of all claims 
for the same patient within the database. This database 
contains all National Health Insurance (NHI) enrolment 
files, claims data and the registry for prescription drugs 
and provides comprehensive information on all individ-
uals covered by the insurance program. This study was 
conducted in accordance with the Helsinki Declaration 
and was evaluated and approved by the local Institutional 
Review Board and ethics committee of Buddhist Dalin 
Tzu Chi Hospital, Taiwan (No. B10004021-2).
study population
Patients, 20–70 years of age, newly diagnosed with type 
2 diabetes between 1998 and 2007 were identified 
(figure 1). To be included, patients with type 2 diabetes 
had to have at least three ambulatory or inpatient claims 
with the International Classification of Disease, 9th 
edition, Clinical Modification (ICD-9- CM) diagnosis 
code 250 and excluding type 1 diabetes (ICD-9- CM 
code 2501). A total of 208 cases with type 2 diabetes 
were then excluded because of prior diagnosis of CRC 
(ICD-9- CM codes colon cancer: 153x, rectal cancer: 
154x). This exclusion was indicated by linking type 2 
diabetes subjects to the catastrophic illness registry. In 
Taiwan, insured residents with major diseases (eg, cancer, 
autoimmune diseases, chronic renal failure) can apply 
for a catastrophic illness certificate that grants exemp-
tion from copayment. Those with a follow- up period <3 
months were also excluded (n=38). Additionally, given 
the protective effect of metformin in decreasing the 
onset of cancer,15 those patients who received in the past 
metformin with an average dose of more than 250 mg per 
day were also excluded (n=14 457). Overall, we identified 
40 041 subjects with new- onset type 2 diabetes.
In Taiwan, only certified Chinese medicine physicians 
are entitled to prescribe CHMs. We used the frequency 
of visits to a Chinese medicine physician to verify the 
CHMs exposure of each subject with type 2 diabetes. 
Those receiving CHMs after their initial diagnosis of 
type 2 diabetes for more than 30 days were identified 
as CHMs users, whereas those treated for 30 days or less 
were considered non- CHMs users.8 Based on this rule, 
15 150 cases were designated as CHMs users. A compar-
ison cohort was randomly selected from the remaining 
insured type 2 diabetes cases without CHMs use. For each 
type 2 diabetes case who received CHMs treatment, one 
control case without CHMs treatment was selected, using 
a 1:1 match based on a propensity score. Propensity scores 
representing the likelihood of receiving CHMs were 
calculated using logistic regression analysis, conditional 
on the baseline covariates listed in table 1. Accordingly, 
an equal number of patients in the CHMs and non- CHMs 
cohorts were analyzed in this study. The index date for 
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Table 1 Demographic data and comorbidity comparison of 
the study subjects
Variables
CHMs non- 
users CHMs users P 
valuen=14 940 (%) n=14 940 (%)
Age, (years) 0.75
  ≤50 5259 (35.2) 5274 (35.3)
  >50 9681 (64.8) 9666 (64.7)
  Mean (SD) 53.93±10.32 53.86±10.42 0.74
Gender 0.50
  Female 8396 (56.2) 8337 (55.8)
  Male 6544 (43.8) 6603 (44.2)
Monthly income 0.51
  Low 5692 (38.1) 5677 (38.0)
  Median 8411 (56.3) 8381 (56.1)
  High 837 (5.6) 882 (5.8)
Residential area 0.28
  Urban 8725 (58.4) 8650 (57.9)
  Suburban 2256 (15.1) 2346 (15.7)
  Rural 3959 (26.5) 3944 (26.5)
Comorbidity
  Hypertension 6917 (46.3) 6872 (46.0) 0.49
  Stroke 1121 (7.5) 1150 (7.7) 0.53
  Heart disease 2928 (19.6) 2928 (19.6) 0.99
  Chronic kidney 
disease
194 (1.3) 194 (1.3) 0.67
  Depression 493 (3.3) 538 (3.6) 0.16
  Rheumatologic 
disorders
105 (0.7) 105 (0.7) 0.77
CHMs, Chinese herbal medicines.
the follow- up period for non- CHMs users was the date 
of the type 2 diabetes diagnosis; the index date for the 
follow- up period for CHMs users was the first date of the 
initiation of CHMs service. The end date of the follow- up 
period for both groups was the earliest of the following: 
(1) having a diagnosis of CRC; (2) withdrawing from the 
insurance program or (3) the date of December 31, 2012.
Covariate assessment
Covariates comprised the baseline sociodemographic 
characteristics and comorbidities. Sociodemographic 
data included patient’s age, sex, income (for estimating 
insurance payments) and urbanization level of the resi-
dential area. Monthly income was stratified into New 
Taiwan Dollar (NTD) ≤17 880; NTD 17 881–NTD 43 900 
and ≥NTD 43 901. Urbanization levels were divided into 
urban (levels 1–2), suburban (levels 3–4) and rural (levels 
5–7). Level 1 refers to the “most urbanized” communi-
ties and level 7 refers to the “least urbanized”.16 Base-
line comorbidities included hypertension (ICD-9- CM 
401–405), stroke (ICD-9- CM 430–438), heart disease 
(ICD-9- CM 410–429), chronic kidney disease (ICD-9- CM 
585), depression (ICD-9- CM 296.2, 296.3, 300.4 and 311) 
and rheumatologic disorders (ICD-9- CM 725–729); all 
were based on each individual’s medical records for the 
1 year prior to initial cohort entry.
statistical analysis
We conducted χ2 test and t- test analyses to examine the 
differences in demographic characteristics and comor-
bidities between patients with type 2 diabetes with and 
without CHMs treatment. The incidence rate of CRC was 
calculated as the number of cases per 1000 person- years 
(PYs). Multivariate Cox proportional hazards regression 
analysis was then applied to compute the HR with 95% 
CI of CRC risk in association with CHMs use. To test the 
robustness of the relationship between CHMs use and 
subsequent CRC risk, we divided the CHMs users into two 
subgroups: those who used CHMs for 30–365 days and 
those who used CHMs for more than 365 days. Analysis 
stratified by age and sex using Cox proportional hazards 
regression was also conducted to assess the HR of CRC 
among those who did and did not receive CHMs. Assump-
tions of the proportional hazards model were verified by 
using plots of log (- log (survival)) function) versus log 
(time) and Schoenfeld residuals versus time. All analyses 
were conducted using SAS V.9.3 software (SAS Institute, 
Cary, North Carolina, USA), at a p<0.05 statistically signif-
icant level.
ResulTs
The CHMs user and non- CHMs user cohorts provided, 
each, data for 14 940 subjects. After the matching proce-
dure with propensity score, no significant differences 
were observed between the two groups on age, sex, 
monthly income, residential area and comorbidities, 
indicating that the two groups were comparable with 
regard to these variables (table 1).
Among all eligible subjects, 610 first episodes of CRC 
occurred, 375 in non- CHMs users and 235 in CHMs users, 
during follow- up periods of 151 745.04 and 135,251.86 
PYs, respectively. The incidence rate of CRC was signifi-
cantly lower in CHMs users than in non- CHMs users 
(1.73 vs 2.47, respectively, per 1000 PYs), with an adjusted 
HR of 0.71 (95% CI 0.60 to 0.84) (table 2). Of note, those 
who used CHMs for more than 365 days had a lower risk 
of CRC (95% CI 0.28 to 0.61) vs non- users by 59%.
Table 3 presents the results from this analysis stratified 
by age and gender. Collectively, a more significant benefi-
cial effect of CHMs was observed among younger subjects, 
irrespective of sex. Furthermore, the multivariable strat-
ified analysis verified that the benefit of CHMs therapy 
for treating CRC was more predominant in males than 
in females, with an adjusted HR of 0.66 and 0.76, respec-
tively (table 3). The 10 most commonly prescribed herbal 
formulae for those with type 2 diabetes are summarized 
in table 4. Among them, one was a single- herb product 
while the remaining products were multiple- herb prod-
ucts. Cox proportional hazards regression analysis 
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Table 2 Crude and adjusted HR of colorectal cancer for patients with type 2 diabetes with and without CHMs treatment
Patient group Event PYs Incidence
Crude HR
(95% CI)
Adjusted HR*
(95% CI)
CHMs non- users 375 151 745.04 2.47 1.00 1
CHMs users 235 135 251.86 1.73 0.70 (0.60 to 0.83) 0.71 (0.60 to 0.84)
  CHMs use for 31–365 days 208 108 166.55 1.92 0.78 (0.66 to 0.93) 0.79 (0.67 to 0.94)
  CHMs use >1 year 27 27 085.31 1.00 0.40 (0.27 to 0.60) 0.41 (0.28 to 0.61)
Incidence rate is per 1000 PYs.
*Model adjusted for age, gender, urbanization level, monthly income and comorbidity.
CHMs, Chinese herbal medicines; PYs, patient- years.
Table 3 Age- specific and sex- specific incidence and adjusted HR of colorectal cancer in relation to CHMs use in patients 
with type 2 diabetes
Variables
CHMs non- users CHMs users
Crude HR (95% CI)
Adjusted HR
(95% CI)Case PYs Incidence Case PYs Incidence
Female
  ≤50 years 33 26 100.8 1.26 17 26 277.02 0.65 0.50 (0.28 to 0.90) 0.50 (0.27 to 0.89)*
  >50 years 154 58 674.38 2.62 107 48 944.48 2.19 0.84 (0.66 to 1.07) 0.84 (0.65 to 1.07)*
  All 187 84 775.18 2.21 124 75 221.5 1.65 0.76 (0.59 to 0.94) 0.76 (0.61 to 0.96)†
Male
  ≤50 years 39 25 323.32 1.54 20 22 241.56 0.90 0.60 (0.35 to 0.98) 0.59 (0.34 to 0.97)*
  >50 years 149 41 646.54 3.58 91 37 788.8 2.41 0.67 (0.52 to 0.87) 0.68 (0.52 to 0.88)*
  All 188 66 969.86 2.81 111 60 030.36 1.85 0.65 (0.52 to 0.83) 0.66 (0.53 to 0.84)†
Incidence rate is per 1000 PYs.
*Model adjusted for urbanization level, monthly income and comorbidity.
†Model adjusted for age, urbanization level, monthly income and comorbidity.
CHMs, Chinese herbal medicines; PYs, person- years.
showed that the use of Huang- Qin, Shu- Jing- Huo- Xue- 
Tang, Xue- Fu- Zhu- Yu- Tang, Ji- Sheng- Shen- Qi- Wan, Liu- 
Wei- Di- Huang- Wan, Gan- Lu- Yin, Shao- Yao- Gan- Cao- Tang 
and Ban- Xia- Xie- Xin- Tang was significantly associated 
with lower risk of CRC (table 4).
dIsCussIOn
This is the first evidence- based cohort study addressing 
the association between CHMs use and CRC risk in 
patients with type 2 diabetes through a large nation-
wide claims- based data source. In this follow- up study 
of 15 years (1998–2012), we found that patients with 
type 2 diabetes who were receiving CHMs had a nearly 
30% lower chance of CRC than those not using CHMs. 
Furthermore, those receiving CHMs for more than 365 
days were found to have a lower risk of CRC by nearly 
60%. The dose- response relationship may elucidate 
the causality between CHMs use and the decrease in 
the predisposition for developing CRC. No previous 
studies have been conducted to determine the long- 
tern impact of CHMs on CRC risk among patients with 
type 2 diabetes, thus rendering a comparison of results 
impossible. However, the findings obtained herein are 
consistent with earlier research findings and add to the 
growing body of knowledge on the beneficial effects of 
CHMs for the patients with chronic diseases.6–8
The effect of CHMs was further analyzed with stratifi-
cation by age and sex. Taken together, the use of CHMs 
was found to have a greater effect on CRC risk in younger 
patients irrespective of their sex, and th finding echod 
these of previous studies.7 8 We speculated that younger 
patients may have fewer coexisting medical conditions or 
possess better medical knowledge and coping resources, 
in addition to demonstrating more positive attitudes 
toward medical impairments,17 thus enhancing the 
preventive impact of CHMs on CRC risk.
An additional contribution of the present study is 
the list of Chinese herbal products that were found 
to be beneficial in reducing CRC risk. For example, 
Huang- Qin is one of the most common CHMs used to 
treat type 2 diabetes and it may help in lessening the 
subsequent risk for CRC. Wogonin, the main ingredient 
in Huang- Qin, was found to have antineoplastic and anti- 
inflammatory effects in both in vitro and in vivo studies. 
One study found that wogonin can induce activation of 
AMP- activated protein kinase (AMPK), to inhibit the 
proliferation and induce apoptosis in cancer cells.18 Addi-
tionally, other researchers have proposed that wogonin 
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Table 4 Risk of colorectal cancer in relation to the 10 most commonly used CHMs for patients with type 2 diabetes
CHMs name Ingredients or generic name
Frequency of 
prescriptions
Crude HR
(95% CI)
Adjusted HR *
(95% CI)
Single- herb products
  Huang- Qin Scutellariae radix 15 796 0.67
(0.52 to 0.84)
0.68
(0.56 to 0.90)
Multiherb products
  Shu- Jing- Huo- 
Xue- Tang
Paeoniae radix, Angelicae radix, Atractylodis lanceae rhizome, Cnidii 
rhizome, Persicae semen, Poria, Rehmanniae radix, Achyranthis 
radix, Clematis radix, Gentianae scabrae radix, Notoptergii rhizome, 
Saposhnikoviae radix, Sinomeni caulis et rhizome, Angelicae dahuricae radix, 
Aurantii nobillis pericarpium, Glycyrrhizae radix, Zingiberis rhizoma
18 503 0.65
(0.54 to 0.78)
0.69
(0.56 to 0.81)
  Xue- Fu- Zhu- Yu- 
Tang
Glycyrrhizae radix, Angelicae sinensis radix, Rehmanniae radix, Achyranthis 
bidentatae radix, Persicae semen, Chuanxiong rhizoma, Platycodonis radix, 
Carthami flos, Paeoniae radix rubra, Bupleuri radix, Aurantii fructus
11 664 0.56
(0.44 to 0.72)
0.60
(0.46 to 0.76)
  Ji- Sheng- Shen- 
Qi- Wan
Rehmanniae radix preparata, Fructus corni, Cortex moutan, Rhizoma 
dioscoreae, Poria and Rhizoma alismatis, Achyranthis bidentatae radix, 
Aconiti lateralis praeparata radix, Cinnamomi cortex, Plantaginis semen
12 498 0.55
(0.42 to 0.72)
0.53
(0.40 to 0.69)
  Liu- Wei- Di- Huang- 
Wan
Rehmanniae radix preparata, Fructus corni, Cortex moutan, Rhizoma 
dioscoreae, Poria, Rhizoma alismatis
11 031 0.58
(0.49 to 0.67)
0.62
(0.53 to 0.72)
  Gan- Lu- Yin Glycyrrhilza uralensis, Liriope spicata, Citrus sinensis, Rehmannia glutinose, 
Artemisia capillaris, Eriobotrya japonica, Dendrobium nobile, Scutellaria 
baicalensis and Asparagus cochinchinensis
9753 0.62
(0.47 to 0.81)
0.64
(0.49 to 0.84)
  Du- Huo- Ji- Sheng 
Tang
Angelicae pubescentis radix, Taxilli herba, Eucommiae cortex, Cyathulae 
radix, Asari radix, Gentianae macrophyllae radix, Poria, Cinnamomi cortex, 
Saposhnikoviae radix, Chuanxiong rhizoma, Ginseng radix, Glycyrrhizae 
radix, Angelicae sinensis radix, Paeoniae radix alba, Rehmanniae radix
9063 0.79
(0.64 to 0.97)
0.76
(0.61 to 1.01)
  Shao- Yao- Gan- 
Cao- Tang
Paeoniae radix, Glycyrrhizae radix 8003 0.74
(0.60 to 0.91)
0.75
(0.57 to 0.89)
  Yu- Quan- Wan Ophiopogonis radix, Ginseng radix, Poria, Astragali radix, Mume fructus, 
Trichosanthis fructus, Glycyrrhizae radix, Puerariae lobatae radix
4932 0.88
(0.56 to 1.13)
0.92
(0.60 to 1.23)
  Ban- Xia- Xie- Xin- 
Tang
Pinelliae rhizoma, Scutellariae radix, Zingiberis rhizoma, Ginseng radix, 
Glycyrrhizae radix, Coptidis rhizoma, Jujubae fructus
4529 0.69
(0.52 to 0.91)
0.70
(0.54 to 0.97)
*Model adjusted for age, gender, urbanization level, monthly income and comorbidities.
CHMs, Chinese herbal medicines.
may suppress the production of interleukin (IL)-6 and 
IL- 1b by modulating the nuclear factor (NF)- kappa beta 
and NF- E2- related factor 2 signaling pathways.19 IL-6 and 
IL-1β are well known pleiotropic proinflammatory cyto-
kines with profound effects on several diseases, especially 
CRC onset.20 21
Findings of the present study revealed that the other 
commonly- prescribed formulas targeting type 2 diabetes, 
such as Xue- Fu- Zhu- Yu- Tang and Shu- Jing- Huo- Xue- 
Tang, also significantly lowered CRC risk. Recently, both 
animal experiments and human studies showed that 
Xue- Fu- Zhu- Yu- Tang has anti- inflammatory and anti- 
tumor effects, primarily via inhibiting the activation of 
such intracellular signaling pathways as phosphoinositide 
3- kinase- protein kinase B- mammalian target of rapa-
mycin (PI3K- AKT- mTOR).22 23 Blocking PI3K- AKT- mTOR 
signaling may impact the expression levels of elements in 
the tumor microenvironment, affecting cancer stem cell 
expression and survival.24 In addition, the positive ther-
apeutic effect of Shu- Jing- Huo- Xue- Tang on subsequent 
risk of CRC may be inferred from its reported effect of 
increasing blood circulation and enhancing antioxidant 
enzymatic activity,25 in addition to its anti- inflammatory 
activity.26 All of these processes have been implicated in 
the development of colitis- associated neoplasia.27
Similar to a previous report,28 the current study showed 
a preventive effect of Liu- Wei- Di- Huang- Wan on the risk 
of CRC. This herbal product may induce the inactiva-
tion of the IGF pathway. IGF is well known to promote 
malignant transformation, promoting cell proliferation 
and dedifferentiation and inhibiting apoptosis, which in 
turn predisposes the individual to developing cancer.29 
Ji- Sheng- Shen- Qi- Wan, also known as Gosha- jinki- gan, is 
widely used to treat patients with diabetic neuropathy. 
This medication enhances nitric oxide (NO) production 
and thereby increases blood circulation while inhibiting 
blood coagulation.30 Recently, NO has been suggested 
to modulate different cancer- related events, including 
angiogenesis, apoptosis and metastasis,31 all possible 
mechanisms for the positive effect observed here.
Gan- Lu- Yin was also found to decrease the risk of CRC. 
In one study, relative to untreated controls, Gan- Lu- 
Yin- fed rats had markedly reduced cell proliferation and 
migration, through the induced differentiation of WEHI-3 
cells.32 This inhibition of angiogenesis may prevent subse-
quent tumor growth. Use of another common CHMs, 
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Shao- Yao- Gan- Cao- Tang, was also related to a lower 
risk of CRC. This compound may rescue the decreased 
phosphorylation of glycogen synthase kinase 3 (GSK-3) 
in patients with type 2 diabetes.33 Activation of GSK-3 
would then downregulate the PI3K- AKT- mTOR signaling 
pathway to inhibit colon cancer cell proliferation.34
Use of Ban- Xia- Xie- Xin- Tang was found to lessen the risk 
of developing CRC in patients with type 2 diabetes. One 
possible mechanism may involve the anti- inflammatory 
properties of Ban- Xia- Xie- Xin- Tang,35 36 which is often 
used to treat various digestive inflammations, like colitis, 
esophagitis and gastritis.37 Chronic inflammation of the 
bowel has been hypothesized as the most important 
mechanism driving CRC onset.38
While our study is the first to investigate CHMs effect on 
reducing CRC risk among patients with type 2 diabetes, 
there are important limitations to consider. First, a 
coding error may occur in the retrospective study design 
due to factors related to the availability and accuracy 
of the medical record. Therefore, we enrolled patients 
with type 2 diabetes and CRC only after these patients 
had at least three outpatient visits reporting consistent 
diagnoses, or after the patients had at least one inpatient 
admission. The CRC cases were further verified using the 
catastrophic illness registry. It should also be noted that 
the Taiwan NHI randomly audits hospital claims, inter-
views patients and reviews medical charts to verify the 
accuracy of medical records. Second, the LHID does not 
include detailed information on the risk factors associ-
ated with CRC, such as smoking, alcohol consumption, 
level of obesity or dietary habits. Future research, consid-
ering these untested variables, is needed to better assess 
whether the present findings are replicable across diverse 
groups of individuals. Third, prescriptions for medications 
issued before 1996 were not reflected in our data analysis. 
This omission may have resulted in underestimation of 
the cumulative frequency of prescriptions and therefore 
may have weakened the apparent effects of the specified 
herbal products. Although several commonly- prescribed 
CHMs for patients with type 2 diabetes were identified 
as influential in decreasing the risk of CRC, their thera-
peutic effect and safety concerns remain to be elucidated 
in future pharmacological investigations. Fourth, we 
conducted two sensitivity analysis to confirm the relation-
ships of interest. First, we did not exclude those receiving 
metformin with an average dose of more than 250 mg per 
day (n=14 457). The reanalysis showed that the protec-
tive effect of CHMs was somewhat attenuated, but was still 
statistically significant (adjusted HR=0.76; 95% CI 0.64 to 
0.89). Second, all CRC cases were divided into two groups 
based on the location of CRC, namely, the occurrence of 
malignant neoplasm of colon and rectal cancer. Of the 
610 CRC cases, 395 were of colon cancer and 215 cases 
were attributed to rectal cancer. After adjusting for the 
confounders, the reanalysis indicated that integrating 
CHMs into the conventional therapy decreased the risk 
of colon cancer and rectal cancer, with an adjusted HR 
of 0.77 (95% CI 0.64 to 0.95) and 0.60 (95% CI 0.45 to 
0.79), respectively. Taken together, the results from the 
reanalysis of the two sensitivity analyses lent support to 
the earlier findings of this study. Fifth, although our study 
revealed a substantial benefit resulting from the use of 
CHMs among patients with type 2 diabetes, it must be 
recognized that in our study patients were not randomly 
categorized into users and nonusers of CHMs. Therefore, 
potential biases may still remain, and in particular when 
they stem from unmeasured or unknown confounders. 
Caution, therefore, must be exercised when interpreting 
these findings.
These limitations notwithstanding, this study also offer 
several strengths. These include the immediate avail-
ability of data, the comprehensiveness of the database, 
and the statistical power derived from the large sample. 
In addition, a long observational period offers the oppor-
tunity to determine in detail the association between 
CHMs usage and CRC risk among patients with type 2 
diabetes, and the available findings may serve as a useful 
reference for future studies focusing on additional clin-
ical outcomes, such as colorectal neoplasm.
COnClusIOn
In summary, this large- scale nationwide cohort study 
demonstrates that the integration of CHMs, during treat-
ment for type 2 diabetes, appears to lower the subsequent 
risk of CRC by nearly 30%. We believe that these find-
ings could serve as a reference for healthcare providers 
in helping to establish more effective therapeutic inter-
ventions to improve the prognosis of patients with type 
2 diabetes.
author affiliations
1Department of Chinese Medicine, Dalin Tzuchi Hospital, The Buddhist Tzuchi 
Medical Foundation, Chiayi, Taiwan
2Department of Biomedical Sciences, National Chung Cheng University, Chiayi, 
Taiwan
3Rehabilitation Counseling Program, Portland State University, Portland, Oregon, 
USA
4Department of Nursing, Dalin Tzuchi Hospital, The Buddhist Tzuchi Medical 
Foundation, Chiayi, Taiwan
5Epigenomics and Human Diseases Research Center, National Chung Cheng 
University, Chiayi, Taiwan
6Division of Allergy, Immunology and Rheumatology, Dalin Tzuchi Hospital, The 
Buddhist Tzuchi Medical Foundation, Chiayi, Taiwan
7School of Medicine, Tzu Chi University, Hualien, Taiwan
8School of Post- Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, 
Taiwan
9Department of Environmental and Occupational Health, College of Medicine, 
National Cheng Kung University, Tainan, Taiwan
10Department of Nursing, Tzu Chi University of Science and Technology, Hualien, 
Taiwan
11Department of Medical Research, Dalin Tzuchi Hospital, The Buddhist Tzuchi 
Medical Foundation, Chiayi, Taiwan
acknowledgements The study is based in part on data from the National Health 
Insurance Research Database provided by the Bureau of National Health Insurance, 
Department of Health and managed by the National Health Research Institutes, in 
Taiwan. The interpretation and conclusions contained herein do not represent those 
of the Bureau of National Health Insurance, Department of Health or National Health 
Research Institutes. JSJ, HL, SYY, HJH and MWYC contributed equally to this work.
Library-Serials. Protected by copyright.
 o
n
 M
ay 20, 2020 at Portland State University
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2019-000732 on 12 March 2020. Downloaded from 
7BMJ Open Diab Res Care 2020;8:e000732. doi:10.1136/bmjdrc-2019-000732
Epidemiology/Health Services Research
Contributors JSJ, SYY and TYT were involved in the study design and drafted 
the manuscript. HL and TYT contributed to data analysis and revised the 
manuscript. MCL, HJH, MWYC and CCY contributed to the interpretation of data and 
provided comments on the final draft of the manuscript. MCL and CCY provided 
administrative support and comments on the manuscript drafts. TYT, HL and JSJ 
were responsible for the study conception, design, data analysis and drafting. All 
authors read and approved the final manuscript.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
ethics approval This study was approved by the Research of Ethics Committee of 
Dalin Tzuchi Hospital (No. B10004021-2).
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement No data are available.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCId id
Tzung- Yi Tsai http:// orcid. org/ 0000- 0002- 9865- 7101
RefeRences
 1 Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes 
atlas: global estimates for the prevalence of diabetes for 2015 and 
2040. Diabetes Res Clin Pract 2017;128:40–50.
 2 González N, Prieto I, Del Puerto- Nevado L, et al. 2017 update on the 
relationship between diabetes and colorectal cancer: epidemiology, 
potential molecular mechanisms and therapeutic implications. 
Oncotarget 2017;8:18456–85.
 3 McGuire S. World cancer report 2014. Geneva, Switzerland: World 
Health organization, International agency for research on cancer, 
who press, 2015. Adv Nutr 2016;7:418–9.
 4 Chang C- H, Lin J- W, Wu L- C, et al. Oral insulin secretagogues, 
insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol 
Metab 2012;97:E1170–5.
 5 Yang Y- X, Hennessy S, Lewis JD. Insulin therapy and 
colorectal cancer risk among type 2 diabetes mellitus patients. 
Gastroenterology 2004;127:1044–50.
 6 Chen K- H, Yeh M- H, Livneh H, et al. Association of traditional 
Chinese medicine therapy and the risk of dementia in patients with 
hypertension: a nationwide population- based cohort study. BMC 
Complement Altern Med 2017;17:178.
 7 Tsai T- Y, Livneh H, Hung T- H, et al. Associations between prescribed 
Chinese herbal medicine and risk of hepatocellular carcinoma in 
patients with chronic hepatitis B: a nationwide population- based 
cohort study. BMJ Open 2017;7:e014571.
 8 Tsai T- Y, Li C- Y, Livneh H, et al. Decreased risk of stroke in patients 
receiving traditional Chinese medicine for vertigo: a population- 
based cohort study. J Ethnopharmacol 2016;184:138–43.
 9 Kostaki E- G, Nikolopoulos GK, Pavlitina E, et al. Molecular 
Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)–Infected 
Individuals in a Network- Based Intervention (Transmission Reduction 
Intervention Project): Phylogenetics Identify HIV-1–Infected 
Individuals With Social Links. J Infect Dis 2018;218:707–15.
 10 Hao C- zi, Wu F, Lu L, et al. Chinese herbal medicine for diabetic 
peripheral neuropathy: an updated meta- analysis of 10 high- quality 
randomized controlled studies. PLoS One 2013;8:e76113.
 11 Xu H- B, Jiang R- H, Chen X- Z, et al. Chinese herbal medicine in 
treatment of diabetic peripheral neuropathy: a systematic review and 
meta- analysis. J Ethnopharmacol 2012;143:701–8.
 12 Huang W- J, Fu Q, Xiao Y- H, et al. Effect of qufengtongluo 
decoction on PI3K/Akt signaling pathway in the kidney of type 2 
diabetes mellitus rat (GK rat) with diabetic nephropathy. Evid Based 
Complement Alternat Med 2018;2018:8421979
 13 Liu H, Liu H, Zhou Z, et al. Herbal formula Huang Qin Ge Gen Tang 
enhances 5- fluorouracil antitumor activity through modulation of the 
E2F1/TS pathway. Cell Commun Signal 2018;16:7.
 14 National health insurance research database, Taiwan. Available: 
http:// nhird. nhri. org. tw/ date_ cohort. html [Accessed 8 May 2018].
 15 Lin T- C, Hwang D- K, Hsu C- C, et al. Protective effect of metformin 
against retinal vein occlusions in diabetes mellitus – a nationwide 
population- based study. PLoS One 2017;12:e0188136.
 16 Liu CY HY, Chuang YL, Chen YJ, et al. Incorporating development 
stratification of Taiwan townships into sampling design of large scale 
health interview survey. J Health Manag 2006;4:1–22.
 17 Lai J- N, Hwang J- S, Chen H- J, et al. Finished herbal product as 
an alternative treatment for menopausal symptoms in climacteric 
women. J Altern Complement Med 2005;11:1075–84.
 18 Lee D- H, Lee TH, Jung CH, et al. Wogonin induces apoptosis 
by activating the AMPK and p53 signaling pathways in human 
glioblastoma cells. Cell Signal 2012;24:2216–25.
 19 Yao J, Zhao L, Zhao Q, et al. NF-κB and Nrf2 signaling pathways 
contribute to wogonin- mediated inhibition of inflammation- 
associated colorectal carcinogenesis. Cell Death Dis 
2014;5:e1283.
 20 Guo P- D, Sun Z- W, Lai H- J, et al. Clinicopathological analysis 
of PD- L2 expression in colorectal cancer. Onco Targets Ther 
2018;11:7635–42.
 21 Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1β 
induces gastric inflammation and cancer and mobilizes myeloid- 
derived suppressor cells in mice. Cancer Cell 2008;14:408–19.
 22 Xing Z, Xia Z, Peng W, et al. Xuefu Zhuyu decoction, a traditional 
Chinese medicine, provides neuroprotection in a rat model of 
traumatic brain injury via an anti- inflammatory pathway. Sci Rep 
2016;6:20040.
 23 Liu J, Zhang J, Huang L, et al. XuefuZhuyu Tang exerts antitumor 
effects by inhibiting glioma cell metastasis and invasion 
via regulating tumor microenvironment. Onco Targets Ther 
2016;9:3603–12.
 24 Martelli AM, Evangelisti C, Chiarini F, et al. Targeting the PI3K/Akt/
mTOR signaling network in acute myelogenous leukemia. Expert 
Opin Investig Drugs 2009;18:1333–49.
 25 Tong Z, Yu F, Liu Z, et al. Influence of ShuJinHuoXue Tablets on 
Ischemia Reperfusion Injury of Animals’ Skeletal Muscle. Molecules 
2012;17:8494–505.
 26 Chou CT, Wu WL, Chang ML, et al. Efficacy and possible 
mechanisms of the Chinese herbs suching- huo- hsuei- tang in the 
treatment of adjuvant- induced arthritis in rats. Am J Chin Med 
1993;21:159–70.
 27 Grivennikov SI. Inflammation and colorectal cancer: colitis- 
associated neoplasia. Semin Immunopathol 2013;35:229–44.
 28 Wu C- T, Tsai Y- T, Lin J- G, et al. Chinese herbal products and the 
reduction of risk of breast cancer among females with type 2 
diabetes in Taiwan: a case- control study. Medicine 2018;97:e11600.
 29 Sachdev D, Yee D. Disrupting insulin- like growth factor signaling as 
a potential cancer therapy. Mol Cancer Ther 2007;6:1–12.
 30 Yoshida N, Hosokawa T, Ishikawa T, et al. Efficacy of goshajinkigan 
for oxaliplatin- induced peripheral neuropathy in colorectal cancer 
patients. J Oncol 2013;2013:139740
 31 Korde Choudhari S, Chaudhary M, Bagde S, et al. Nitric oxide and 
cancer: a review. World J Surg Oncol 2013;11:118.
 32 Liu F- C, Pan C- H, Lai M- T, et al. Gan- Lu- Yin inhibits proliferation 
and migration of murine WEHI-3 leukemia cells and tumor growth 
in BALB/c allograft tumor model. Evid Based Complement Alternat 
Med 2013;2013:1–13.
 33 Tsai F- J, Ho T- J, Cheng C- F, et al. Characteristics of Chinese herbal 
medicine usage in ischemic heart disease patients among type 2 
diabetes and their protection against hydrogen peroxide- mediated 
apoptosis in H9c2 cardiomyoblasts. Oncotarget 2017;8:15470–89.
 34 Jain S, Ghanghas P, Rana C, et al. Role of GSK-3β in regulation 
of canonical Wnt/β-catenin signaling and PI3- K/AKT oncogenic 
pathway in colon cancer. Cancer Invest 2017;35:473–83.
 35 Chen F- pey, Chen F- jou, Jong M- shiou, et al. Modern use of 
Chinese herbal formulae from Shang- Han LUN. Chin Med J 
2009;122:1889–94.
 36 Yang M, Chen J, Xu L, et al. A network pharmacology approach to 
uncover the molecular mechanisms of herbal formula ban- xia- xie- 
xin- tang. Evid Based Complement Alternat Med 2018;2018:1–22.
 37 Zhao L, Zhang S, Wang Z, et al. Efficacy of modified ban XIa xie xin 
decoction on functional dyspepsia of cold and heat in complexity 
syndrome: a randomized controlled trial. Evid Based Complement 
Alternat Med 2013;2013:812143
 38 Lakatos P- L, Lakatos L. Risk for colorectal cancer in ulcerative 
colitis: changes, causes and management strategies. World J 
Gastroenterol 2008;14:3937–47.
Library-Serials. Protected by copyright.
 o
n
 M
ay 20, 2020 at Portland State University
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2019-000732 on 12 March 2020. Downloaded from 
